Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
87 hedge funds and large institutions have $184M invested in Osiris Therapeutics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 43 increasing their positions, 19 reducing their positions, and 8 closing their positions.
126% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 19
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
19% more capital invested
Capital invested by funds: $155M → $184M (+$28.7M)
5% more funds holding
Funds holding: 83 → 87 (+4)
94% less call options, than puts
Call options by funds: $361K | Put options by funds: $6.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
+$2.59M |
| 2 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$1.59M |
| 3 |
Renaissance Technologies
New York
|
+$1.56M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$1.3M |
| 5 |
AI
Axiom Investors
Greenwich,
Connecticut
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.89M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.3M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$821K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$715K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$464K |
OSIR Hedge Fund Activity: Q2 2015 in Review
87 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q2 2015, worth a combined $184M — up 19% from $155M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new OSIR positions and 8 closed out — a net gain of 4 holders — while 43 added to existing stakes and 19 trimmed.
The largest buyer was Charles Schwab, adding an estimated $2.59M. The largest seller was Citadel Advisors, cutting an estimated $1.89M.
- 87 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q2 2015, up from 83 in Q1 2015.
- Funds reported $184M of Osiris Therapeutics, Inc. Common Stock stock for Q2 2015, up 19% quarter-over-quarter.
- 12 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q2 2015 and 8 closed out, a net change of +4 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q2 2015 was Charles Schwab, an estimated $2.59M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q2 2015 was Citadel Advisors, an estimated $1.89M sold.
Based on aggregated 13F filings for Q2 2015.